Executive Committee

Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

Dr. Noah Berkowitz is Chief Medical Officer at Arvinas and responsible for clinical development of the company’s PROTAC® protein degrader programs in oncology and neuroscience. Dr. Berkowitz has more than 20 years of experience in advancing programs through early and late stages of development, with proven ability in leading clinical development, regulatory, and medical affairs. He has led multidisciplinary teams and has extensive knowledge of clinical trial design and execution.

Prior to joining Arvinas, Dr. Berkowitz was Senior Vice President and Development Unit Head of Hematology at Bristol-Myers Squibb (BMS). While at BMS, Dr. Berkowitz’s teams achieved initial or subsequent global indications for Abecma^®, Breyanzi^®, Reblozyl^®, Onureg^®, and Inrebic^®, managed development life cycles for Revlimid^®, Pomalyst^®, and Sprycel^®, and initiated and/or designed registration trials for iberdomide, mezigdomide, and alnuctamab. Before BMS, Dr. Berkowitz held roles of increasing responsibility in the areas of oncology, rare diseases, and hematology at Novartis, most recently as Vice President and Clinical Development Head for Hematology. Earlier in his career, Dr. Berkowitz was an executive at Impath (acquired by Genzyme) and founder and Chief Executive Officer of Synvista.

Dr. Berkowitz trained in Medical Oncology at the National Cancer Institute and received his M.D., Ph.D., from Columbia University.